Roche’s oral PI3K inhibitor Itovebi (inavolisib) has been approved by the European Commission (EC) as part of a combination ...

Up to 40% of ER-positive breast cancers have a PIK3CA mutation and are associated with poor prognosis; this approval helps address an urgent unmet need2-4 Itovebi is the first PI3K-targeted therapy to ...

Menopause can feel like one big balancing act. Between managing your hormone levels and symptoms like hot flashes, night ...

YourChoice Therapeutics, Inc., pioneering hormone-free family planning products, today announced that Communications Medicine ...